Intravascular delivery of nucleic acid
View Patent ↗Disclosed is a process for providing for expression of an exogenous nucleic acid in an extravascular parenchymal cell of a mammal. The nucleic acid is inserted into a vessel of a mammal and the permeability of the vessel is increased. Increasing permeability of the vessel allows delivery of the nucleic acid to an extravascular parenchymal cell.
1. An in vivo process for delivering a nucleic acid to an extravascular cell in a limb of a mammal, comprising:
a) forming a complex containing the nucleic acid in a pharmaceutically acceptable solution;
b) inserting an injection devise into a vessel in the limb;
c) applying a device to occlude blood flow externally around the limb;
d) occluding blood flow to an from the limb; and,
e) injecting the solution through the injector into the vessel thereby increasing permeability of the blood vessel, passing the nucleic acid though the blood vessel and delivering the nucleic acid to the extravascular cell.
2. The process of claim 1 wherein increasing the permeability of the vessel consists of increasing pressure against vessel walls.
3. The process of claim 2 wherein increasing the pressure consists of increasing a volume of fluid within the vessel.
4. The process of claim 1 wherein said device for impeding blood flow is selected from the group consisting of: tourniquet, double tourniquet, double cuff tourniquet, cuff, sphygmomanometer, oscillotonormeter, oscillometer, and haemotonormeter.
5. The process of claim 1 wherein the complex consists of a virus.
6. The process of claim 1 wherein the complex consists of a non-viral complex.
7. The process of claim 1 wherein the nucleic acid consists an oligonucleotide.
8. The process of claim 1 wherein the nucleic acid consists of double stranded nucleic acid.
9. The process of claim 1 wherein the nucleic acid consists of single stranded nucleic acid.
10. The process of claim 1 wherein the nucleic acid is selected from the list consisting of RNA, double strand RNA, siRNA, microRNA, and antisense nucleic acid.
11. The process of claim 1 wherein the extravascular cell consists of a muscle cell.
12. The process of claim 11 wherein the muscle cell consists of an arm muscle cell.
13. The process of claim 12 wherein the arm muscle cell is selected from the group consisting of palmaris longus muscle cell, pronator teres muscle cell, flexor carpi radialis muscle cell, flexor carpi ulnaris muscle cell, and flexor digitorum superficialis muscle cell.
14. The process of claim 12 wherein the arm muscle cell is selected from the group consisting of flexor digitorum profundus muscle cell, and pronator quadratus muscle cell.
15. The process of claim 12 wherein the arm muscle cell is selected from the group consisting of brachioradialis muscle cell, extensor carpi radialis longus muscle cell, extensor carpi radialis brevis muscle cell, extensor digitorum muscle cell, anconeus muscle cell, extensor carpi ulnaris muscle cell, and extensor pollicis longus muscle cell.
16. The process of claim 12 wherein the arm muscle cell is selected from the group consisting of supinator muscle cell, abductor pollicis longus muscle cell, extensor digiti secund et teriti muscle cell, and extensor digiti quart et minimi muscle cell.
17. The process of claim 11 wherein the muscle cell consists of an hand muscle cell.
18. The process of claim 17 wherein the hand muscle cell consists of a thumb muscle cell.
19. The process of claim 17 wherein the hand skeletal muscle cell is consists of an interosseus muscle cell.
20. The process of claim 11 wherein the muscle cell consists of a leg muscle cell.
21. The process of claim 20 wherein the leg skeletal muscle cell is selected from the group consisting of gastrocnemius muscle cell and soleus muscle cell.
22. The process of claim 20 wherein the leg skeletal muscle cell is selected from the group consisting of popliteus muscle cell, flexor digitorum longus muscle cell, flexor hallucis longus muscle cell, and tibialis posterior muscle cell.
23. The process of claim 20 wherein the leg skeletal muscle cell is selected from the group consisting of tibialis anterior muscle cell, extensor hallucis longus muscle cell, extensor digitorum longus muscle cell, and abductor hallucis longus muscle cell.
24. The process of claim 20 wherein the leg skeletal muscle cell is selected from the group consisting of peronaus longus muscle cell and peronaus brevis muscle cell.
25. The process of claim 11 wherein the muscle cell consists of a foot muscle cell.
26. The process of claim 25 wherein the foot skeletal muscle cell is selected from the group consisting of extensor digitorum brevis muscle cell and extensor hallucis brevis muscle cell.
27. The process of claim 1 further comprising administering immunosuppressive drugs to the mammal.
28. The process of claim 6 wherein non-viral complex comprises the nucleic acid and a cationic polymer.
29. The process of claim 28 wherein the cationic polymer consists of a polyamine.
30. The process of claim 29 wherein the polyamine is selected from the group consisting of histone, polvethyleneimine, poly-L-lysine, poly-histidine, and protamines.
31. The process of claim 6 wherein non-viral complex comprises the nucleic acid and a cationic lipid.
32. The process of claim 31 wherein non-viral complex consists of a lipopolyplex.
33. The process of claim 6 wherein the non-viral complex comprises the nucleic acid, a polycation and a polyanion.
34. The process of claim 33 wherein the net charge of the complex is negative.
35. The process of claim 6 wherein the non-viral complex comprises the nucleic acid, a cationic lipid and a polyanion.
36. The process of claim 35 wherein the net charge of the non-viral complex is negative.